Cosciens Biopharma Inc (CSCIF)

[nit2winit26]

Quebec City, Canada, September 21, 2015 – Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the “Company”) announced today that it has entered into definitive agreements with the holders (the “Consenting Holders”) of approximately 90% of its outstanding Series B Common Share Purchase Warrants (the “Series B Warrants”) that are intended to reduce the dilutive effect of the exercise of the Series B Warrants by establishing a cap on the number of shares issuable upon alternate net cashless exercise (“Net Cashless Exercise”) of the Series B Warrants until the close of business on November 17, 2015